Abcam, ab274430, Anti-Synapsin I antibody [EPR23531-50] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Synapsin I antibody. Carrier free. Suitable for ICC/IF, IP, WB, IHC-P, IHC-Fr, Flow Cyt (Intra), mIHC and reacts with Rat, Mouse, Human samples. Cited in 3 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23531-50,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:IP, mIHC, ICC/IF, IHC-Fr, IHC-P, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab274430 is the carrier-free version of
ab254349
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Synapsin I also known as SYN1 plays an important role in synaptic function. It is a phosphoprotein with a molecular mass of approximately 78 kDa. Synapsin I is expressed mainly in the neurons of the central nervous system (CNS). It binds to synaptic vesicles and actin cytoskeleton which suggests that it functions in modulating neurotransmitter release at the presynaptic terminals. This modulation occurs as synapsin I undergoes phosphorylation which is critical for its activity.
Biological function summary
Synapsin I influences synaptic plasticity and is part of the synaptic vesicle trafficking complex. In its dephosphorylated state Synapsin I associates with synaptic vesicles anchoring them to the actin cytoskeleton. Upon phosphorylation Synapsin I changes conformation causing vesicles to mobilize. This activity supports the modulation of neurotransmitter release impacting learning and memory functions.
Pathways
Synapsin I participates significantly in the neurotransmitter release cycle and synaptic vesicle trafficking pathway. Protein kinase A (PKA) and Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulate its phosphorylation affecting how Synapsin I contributes to vesicle release. The phosphorylation of Synapsin I at sites such as serine 9 enables its interaction with other proteins like actin and spectrin facilitating vesicle movement.
Altered Synapsin I expression associates with neurological conditions like epilepsy and schizophrenia. In epilepsy dysregulation of Synapsin I phosphorylation processes can result in imbalanced neurotransmitter release potentially leading to seizures. Its connection to schizophrenia involves changes in synaptic plasticity which neurotransmitter systems such as dopamine and related proteins like alpha-synuclein also influence. Understanding these interactions can aid in developing therapeutic strategies.